HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

J. Biol. Chem., Vol. 276, Issue 14, 10641-10645, April 6, 2001

This Article Full Text Full Text (PDF) All Versions of this Article: 276/14/10641    most recent M007178200v1 Submit a Letter to Editor Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Damia, G. Articles by Broggini, M. Search for Related Content PubMed PubMed Citation Articles by Damia, G. Articles by Broggini, M. Social Bookmarking                      What's this?

DNA Damage Induces p53-dependent Down-regulation of hCHK1^*

Giovanna Damia^§, Yolanda Sanchez^¶, Eugenio Erba, and Massimo Broggini

From the  Molecular Pharmacology Unit, Department of Oncology, Istituto di Ricerche Farmacologiche "Mario Negri," Via Eritrea 62, 20157 Milan, Italy and the ^¶ Department of Molecular Genetics, University of Cincinnati MSB 3005, Cincinnati, Ohio 45267

The levels of the human checkpoint gene hCHK1 were measured in human cancer cells growing in vitro after treatment with the DNA damaging agent cis-dichlorodiammine platinum(II) (DDP). Treatment of human cancer cell lines with DDP induced a decrease in the hCHK1 protein levels starting 6 h after treatment, with a further decline at 24 and 48 h. A similar decrease in the levels of hCHK1 was found at the mRNA level by using Northern blot analysis. By using isogenic cell systems in which p53 was disrupted either by transfection with HPV-E6 or by targeted homologous recombination, we found that the DNA damage-induced down-regulation of hCHK1 was only observable in wild type p53-expressing cells, with only a minor decline in the hCHK1 levels observable 48 h after treatment in cells with disrupted p53. Similarly, treatment of mutant p53-expressing human cancer cell lines with DDP did not result in changes in the levels of hCHK1. The p53-dependent down-regulation of hCHK1 is likely to be at transcriptional levels, as suggested by the lack of down-regulation of the hCHK1 when transfected under the control of a heterologous viral promoter. In addition, p53 is able to down-regulate the luciferase activity under the control of the 5' flanking region of the hCHK1 gene. The data suggest a strict link between p53 and hCHK1 governing the activation and repression of the G₂ checkpoint in which both proteins participate.

CiteULike

Complore

Connotea

Del.icio.us

Digg

Reddit

Technorati

This article has been cited by other articles:

				H. Gali-Muhtasib, D. Kuester, C. Mawrin, K. Bajbouj, A. Diestel, M. Ocker, C. Habold, C. Foltzer-Jourdainne, P. Schoenfeld, B. Peters, et al. Thymoquinone Triggers Inactivation of the Stress Response Pathway Sensor CHEK1 and Contributes to Apoptosis in Colorectal Cancer Cells Cancer Res., July 15, 2008; 68(14): 5609 - 5618. [Abstract] [Full Text] [PDF]

				C.-M. Aliouat-Denis, N. Dendouga, I. Van den Wyngaert, H. Goehlmann, U. Steller, I. van de Weyer, N. Van Slycken, L. Andries, S. Kass, W. Luyten, et al. p53-Independent Regulation of p21Waf1/Cip1 Expression and Senescence by Chk2 Mol. Cancer Res., November 1, 2005; 3(11): 627 - 634. [Abstract] [Full Text] [PDF]

				H. Fan, J. R. Harrell, S. Dipp, Z. Saifudeen, and S. S. El-Dahr A novel pathological role of p53 in kidney development revealed by gene-environment interactions Am J Physiol Renal Physiol, January 1, 2005; 288(1): F98 - F107. [Abstract] [Full Text] [PDF]

				K. Lohr, C. Moritz, A. Contente, and M. Dobbelstein p21/CDKN1A Mediates Negative Regulation of Transcription by p53 J. Biol. Chem., August 29, 2003; 278(35): 32507 - 32516. [Abstract] [Full Text] [PDF]

				B. S. Cummings and R. G. Schnellmann Cisplatin-Induced Renal Cell Apoptosis: Caspase 3-Dependent and -Independent Pathways J. Pharmacol. Exp. Ther., July 1, 2002; 302(1): 8 - 17. [Abstract] [Full Text] [PDF]